Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

14P - Preclinical evaluation of intermittent dosing regimens on antitumor and PD activity of SY-5609, a potent and selective oral CDK7 inhibitor, in ovarian cancer xenografts

Date

16 Sep 2021

Session

ePoster Display

Topics

Translational Research

Tumour Site

Presenters

Liv Johannessen

Citation

Annals of Oncology (2021) 32 (suppl_5): S361-S375. 10.1016/annonc/annonc684

Authors

L. Johannessen1, W. Dworakowski2, P. Sawant1, N. Ke3, A. Lefkovith1, A. D'Ippolito4, M. Eaton4, S.H. Henry1, G. Hodgson3

Author affiliations

  • 1 Translational Medicine, Syros Pharmaceuticals, 02140 - Cambridge/US
  • 2 Biology, Syros Pharmaceuticals, 02140 - Cambridge/US
  • 3 Translational Medicine, Syros Pharmaceuticals, Cambridge/US
  • 4 Computational Biology, Syros Pharmaceuticals, Cambridge/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 14P

Background

Selective CDK7 inhibition has been shown to target two fundamental processes in cancer: transcription and cell cycle control. SY-5609 is a potent and selective CDK7 inhibitor in Ph1 clinical development in patients with advanced solid tumors including ovarian cancer (NCT04247126). Here we report on the impact of intermittent SY-5609 dosing regimens on tumor growth inhibition (TGI), pharmacodynamic (PD) activity, and pharmacokinetics (PK) in a xenograft model of high grade serous ovarian cancer (HGSOC).

Methods

TGI was compared in OVCAR3 xenografts across a range of SY-5609 doses (1, 3, 6 mpk) and schedules (continuous daily [QD], 5d per wk [5/2], and 7d per wk every other wk [7/7]), and the same total daily dose was evaluated twice daily (BID) vs QD on a continuous schedule. Steady state tumor PK and PD (POLR2A and E2F1 expression) were assessed 8-72 hours after the 5th QD dose in separate mice.

Results

SY-5609 induced dose dependent TGI across all dosing regimens. Higher doses on 5/2 and 7/7 schedules led to TGI or regressions consistent with lower doses given QD. SY-5609 dose-dependent changes in tumor PD markers were sustained above baseline for up to 72 hours. TGI was enhanced when the same total daily dose was administered BID versus QD. Evaluation of SY-5609 PK during BID and QD schedules demonstrated increased antitumor activity associated with maintenance of higher trough levels of SY-5609. All regimens were well tolerated with no body weight loss.

Conclusions

SY-5609 shows robust antitumor activity in preclinical HGSOC xenografts across schedules that integrate higher doses with dosing holidays, supported by sustained PD effects in tumor tissue after dose cessation. Enhanced SY-5609 antitumor activity observed BID vs. QD (controlled for dose) supports the contribution of sustained higher levels of CDK7 inhibition between doses to antitumor activity, and informs the evaluation of intermittent dosing in patients to optimize single agent or combination SY-5609 dose and schedule selection. SY-5609 results of intermittent dosing regimens in patients with advanced solid tumors are reported separately (Sharma, ESMO 2021).

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Syros Pharmaceuticals.

Funding

Syros Pharmaceuticals.

Disclosure

L. Johannessen, W. Dworakowski, P. Sawant, A. Lefkovith, A. D'Ippolito, M. Eaton, S.H. Henry, G. Hodgson: Financial Interests, Institutional, Full or part-time Employment: Syros Pharmaceuticals. N. Ke: Financial Interests, Personal and Institutional, Full or part-time Employment: Syros Pharmaceuticals.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.